Elevated blood β-2 microglobulin is associated with tumor monosomy-3 in patients with primary uveal melanoma

Melanoma Research

Volumn 23, Issue 1, 2013, Pages 1-7

  Triozzi, Pierre L ^a   Elson, Paul ^b   Aldrich, Wayne ^a   Achberger, Susan ^a   Tubbs, Raymond ^b   Biscotti, Charles V ^b   Singh, Arun D ^b  

^a TAUSSIG CANCER INSTITUTE   (United States)

^b LERNER RESEARCH INSTITUTE   (United States)

Author keywords

Blood biomarkers; Insulin like growth factor; Prognosis

Indexed keywords

BETA 2 MICROGLOBULIN; HLA A1 ANTIGEN; SOMATOMEDIN BINDING PROTEIN 3; SOMATOMEDIN C;

ADULT; AGED; ARTICLE; BLOOD ANALYSIS; BRACHYTHERAPY; CANCER GRADING; CANCER PROGNOSIS; CHOROID; CHROMOSOME 3; DISEASE ASSOCIATION; ENUCLEATION; ENZYME LINKED IMMUNOSORBENT ASSAY; EPITHELIOID CELL; FEMALE; FINE NEEDLE ASPIRATION BIOPSY; FLUORESCENCE IN SITU HYBRIDIZATION; HUMAN; HUMAN TISSUE; IN VIVO STUDY; MAJOR CLINICAL STUDY; MALE; MONOSOMY; PREDICTIVE VALUE; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN BLOOD LEVEL; TUMOR LOCALIZATION; TUMOR MONOSOMY 3; TUMOR VOLUME; UVEA MELANOMA;

ADULT; AGED; AGED, 80 AND OVER; BETA 2-MICROGLOBULIN; BRACHYTHERAPY; CHROMOSOME DELETION; CHROMOSOMES, HUMAN, PAIR 3; EYE ENUCLEATION; FEMALE; HUMANS; INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN 3; INSULIN-LIKE GROWTH FACTOR I; LOGISTIC MODELS; MALE; MELANOMA; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEOPLASM GRADING; PROGNOSIS; TUMOR MARKERS, BIOLOGICAL; UVEAL NEOPLASMS; YOUNG ADULT;

EID: 84872075388     PISSN: 09608931     EISSN: 14735636     Source Type: Journal    
DOI: 10.1097/CMR.0b013e32835b7154     Document Type: Article

References (36)

1. Turell ME, Tubbs RR, Biscotti CV, Singh AD. Uveal melanoma: Prognostication. Monogr Clin Cytol 2012; 21:55-60
2. Shields CL, Ganguly A, Materin MA, Teixeira L, Mashayekhi A, Swanson LA, et al. Chromosome 3 analysis of uveal melanoma using fine-needle aspiration biopsy at the time of plaque radiotherapy in 140 consecutive cases: The Deborah Iverson, MD, Lectureship. Arch Ophthalmol 2007; 125:1017-1024 (Pubitemid 47258031)
3. Damato B, Coupland SE. Translating uveal melanoma cytogenetics into clinical care. Arch Ophthalmol 2009; 127:423-429
4. Onken MD, Worley LA, Tuscan MD, Harbour JW. An accurate, clinically feasible multi-gene expression assay for predicting metastasis in uveal melanoma. J Mol Diagn 2010; 12:461-468
5. Schoenfield L, Pettay J, Tubbs RR, Singh AD. Variation of monosomy-3 status within uveal melanoma. Arch Pathol Lab Med 2009; 133: 1219-1222
6. Dopierala J, Damato BE, Lake SL, Taktak AF, Coupland SE. Genetic heterogeneity in uveal melanoma assessed by multiplex ligation-dependent probe amplification. Invest Ophthalmol Vis Sci 2010; 51:4898-4905
7. All-Ericsson C, Girnita L, Seregard S, Bartolazzi A, Jager MJ, Larsson O. Insulin-like growth factor-1 receptor in uveal melanoma: A predictor for metastatic disease and a potential therapeutic target. Invest Ophthalmol Vis Sci 2002; 43:1-8 (Pubitemid 34032432)
8. Mallikarjuna K, Pushparaj V, Biswas J, Krishnakumar S. Expression of insulinlike growth factor receptor (IGF-1R), c-Fos, and c-Jun in uveal melanoma: An immunohistochemical study. Curr Eye Res 2006; 31:875-883 (Pubitemid 44581310)
9. Blom DJ, Luyten GP, Mooy C, Kerkvliet S, Zwinderman AH, Jager MJ. Human leukocyte antigen class I expression. Marker of poor prognosis in uveal melanoma. Invest Ophthalmol Vis Sci 1997; 38:1865-1872 (Pubitemid 27382354)
10. Ericsson C, Seregard S, Bartolazzi A, Levitskaya E, Ferrone S, Kiessling R, Larsson O. Association of HLA class I and class II antigen expression and mortality in uveal melanoma. Invest Ophthalmol Vis Sci 2001; 42: 2153-2156 (Pubitemid 32848839)
11. Edge SB, Byrd DR, Compton CC, Fritz AG, Green FL, Trotti A. Malignant melanoma of the uvea. The AJCC cancer staging handbook. 7th ed. New York: Springer; 2010. pp. 611-622
12. Renehan AG, Zwahlen M, Minder C, O'Dwyer ST, Shalet SM, Egger M. Insulin-like growth factor (IGF)-I, IGF binding protein-3, and cancer risk: Systematic review and meta-regression analysis. Lancet 2004; 363: 1346-1353
13. Egan KM, Giovanucci E, Gragoudas ES, Pollak M. Role of serum insulin-like growth factor (IGF)-1 in the progression of choroidal melanoma [ARVO Abstract]. Invest Ophthalmol Vis Sci 2000;41Abstract 2017
14. Topcu-Yilmaz P, Kiratli H, Saglam A, Söylemezoglu F, Hascelik G. Correlation of clinicopathological parameters with HGF, c-Met, EGFR, and IGF-1R expression in uveal melanoma. Melanoma Res 2010; 20:126-132
15. Krishnakumar S, Abhyankar D, Lakshmi SA, Pushparaj V, Shanmugam MP, Biswas J. HLA expression in choroidal melanomas: Correlation with clinicopathological features. Curr Eye Res 2004; 28:409-416 (Pubitemid 39090324)
16. Bataille R, Durie BG, Grenier J. Serum beta2 microglobulin and survival duration in multiple myeloma: A simple reliable marker for staging. Br J Haematol 1983; 55:439-447 (Pubitemid 14242342)
17. Federico M, Bellei M, Marcheselli L, Luminari S, Lopez-Guillermo A, Vitolo U, et al. Follicular lymphoma international prognostic index 2: A new prognostic index for follicular lymphoma developed by the international follicular lymphoma prognostic factor project. J Clin Oncol 2009; 27:4555-4562
18. Tsimberidou AM, Kantarjian HM, Wen S, O'Brien S, Cortes J, Wierda WG, et al. The prognostic significance of serum beta2 microglobulin levels in acute myeloid leukemia and prognostic scores predicting survival: Analysis of 1180 patients. Clin Cancer Res 2008; 14:721-730 (Pubitemid 351231153)
19. Sabbioni ME, Siegrist HP, Bacchi M, Bernhard J, Castiglione M, Thürlimann B, et al. Association between immunity and prognostic factors in early stage breast cancer patients before adjuvant treatment. Breast Cancer Res Treat 2000; 59:279-287 (Pubitemid 30243050)
20. Frater JL, Tsiftsakis EK, Hsi ED, Pettay J, Tubbs RR. Use of novel t(11;14) and t(14;18) dual-fusion fluorescence in situ hybridization probes in the differential diagnosis of lymphomas of small lymphocytes. Diagn Mol Pathol 2001; 10:214-222 (Pubitemid 33123929)
21. Turell ME, Tubbs RR, Saunthararajah Y, Biscotti CV, Triozzi PL, Singh AD. Improved detection of monosomy-3 in uveal melanoma using double-target FISH with centromeric and 3p25 probes [ARVO Abstract]. Invest Ophthalmol Vis Sci 2011; 52:E-Abstract 1435
22. Barak V, Kaiserman I, Frenkel S, Hendler K, Kalickman I, Pe'er J. The dynamics of serum tumor markers in predicting metastatic uveal melanoma (part 1). Anticancer Res 2011; 31:345-349
23. Hendler K, Pe'er J, Kaiserman I, Baruch R, Kalickman I, Barak V, Frenkel S. Trends in liver function tests: A comparison with serum tumor markers in metastatic uveal melanoma (part 2). Anticancer Res 2011; 31:351-357
24. Metzelaar-Blok JA, Jager MJ, Moghaddam PH, van der Slik AR, Giphart MJ. Frequent loss of heterozygosity on chromosome 6p in uveal melanoma. Hum Immunol 1999; 60:962-969 (Pubitemid 29518120)
25. Singh AD, Sisley K, Xu Y, Li J, Faber P, Plummer SJ, et al. Reduced expression of autotaxin predicts survival in uveal melanoma. Br J Ophthalmol 2007; 91:1385-1392 (Pubitemid 47492881)
26. Bröcker EB, Suter L, Brüggen J, Ruiter DJ, Macher E, Sorg C. Phenotypic dynamics of tumor progression in human malignant melanoma. Int J Cancer 1985; 36:29-35 (Pubitemid 15028611)
27. Claësson MH, Nissen MH. Binding of human beta 2-microglobulin to murine EL4 thymoma cells upregulates MHC class I heavy-chain epitopes, inhibits IL-2 secretion and induces resistance to killing by natural killer cells. Immunol Lett 1994; 39:195-202
28. Josson S, Nomura T, Lin JT, Huang WC,Wu D, Zhau HE, et al. b2-microglobulin induces epithelial to mesenchymal transition and confers cancer lethality and bone metastasis in human cancer cells. Cancer Res 2011; 71:2600-2610
29. Hofmann MA, Kiecker F, Küchler I, Kors C, Trefzer U. Serum TNF-a, B2M and sIL-2R levels are biological correlates of outcome in adjuvant IFN-a2b treatment of patients with melanoma. J Cancer Res Clin Oncol 2011; 137:455-462
30. Girnita A, All-Ericsson C, Economou MA, Aström K, Axelson M, Seregard S, et al. The insulin-like growth factor-I receptor inhibitor picropodophyllin causes tumor regression and attenuates mechanisms involved in invasion of uveal melanoma cells. Clin Cancer Res 2006; 12:1383-1391 (Pubitemid 43342532)
31. Jacobs ET, Marti'nez ME, Alberts DS, Ashbeck EL, Gapstur SM, Lance P, Thompson PA. Plasma insulin-like growth factor I is inversely associated with colorectal adenoma recurrence: A novel hypothesis. Cancer Epidemiol Biomarkers Prev 2008; 17:300-305 (Pubitemid 351272779)
32. Barak V, Zloto O, Pe'er J, Kalickman I, Frenkel S. Insulin like growth factor-1 as a predicting biomarker for metastatic uveal melanoma in humans [ARVO Abstract]. Invest Ophthalmol Vis Sci 2011; 52:E-Abstract 1449
33. Panasiti V, Naspi A, Devirgiliis V, Curzio M, Roberti V, Curzio G, et al. Correlation between insulin-like growth factor binding protein-3 serum level and melanoma progression. J Am Acad Dermatol 2011; 64:865-872
34. Matos AC, Durao MS Jr, Pacheco-Silva A. Serial beta-2-microglobulin measurement as an auxiliary method in the early diagnosis of cytomegalovirus infection in renal transplant patients. Transplant Proc 2004; 36:894-895 (Pubitemid 38766213)
35. Yi Q. Novel immunotherapies. Cancer J 2009; 15:502-510
36. Karasic TB, Hei TK, Ivanov VN. Disruption of IGF-1R signaling increases TRAIL-induced apoptosis: A new potential therapy for the treatment of melanoma. Exp Cell Res 2010; 316:1994-2007